Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (241-250 of 391) with videos related to

Pageof 40
Sort By:
JAMA|December 8, 2020
Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical TrialAndrew M Wilson, Allan B Clark, Tony Cahn, et al.
Thorax|June 18, 2011
In search of the fibrotic epithelial cell: opportunities for a collaborative networkGisli Jenkins, Andrew Blanchard, Zea Borok, et al.
Trials|February 7, 2018
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trialMatthew Hammond, Allan B Clark, Anthony P Cahn, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
The European Respiratory Journal|November 9, 2019
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx TrialJennifer A Whitty, Jenny Rankin, Dina Visca, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 15, 2013
Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patientsThida Win, Benjamin A Thomas, Tryphon Lambrou, et al.
The Lancet. Respiratory Medicine|April 7, 2023
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?Felix Chua, Suying Low, Gin Tsen Chai, et al.
American Journal of Respiratory and Critical Care Medicine|October 11, 2024
Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical TrialTamera J Corte, Juergen Behr, Vincent Cottin, et al.
The European Respiratory Journal|March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trialMarlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
Pageof 40

Showing results (241-250 of 391) with videos related to

Sort By:
Pageof 40
JAMA|December 8, 2020
Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical TrialAndrew M Wilson, Allan B Clark, Tony Cahn, et al.
Thorax|June 18, 2011
In search of the fibrotic epithelial cell: opportunities for a collaborative networkGisli Jenkins, Andrew Blanchard, Zea Borok, et al.
Trials|February 7, 2018
The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trialMatthew Hammond, Allan B Clark, Anthony P Cahn, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
The European Respiratory Journal|November 9, 2019
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx TrialJennifer A Whitty, Jenny Rankin, Dina Visca, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 15, 2013
Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patientsThida Win, Benjamin A Thomas, Tryphon Lambrou, et al.
The Lancet. Respiratory Medicine|April 7, 2023
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?Felix Chua, Suying Low, Gin Tsen Chai, et al.
American Journal of Respiratory and Critical Care Medicine|October 11, 2024
Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical TrialTamera J Corte, Juergen Behr, Vincent Cottin, et al.
The European Respiratory Journal|March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trialMarlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
Pageof 40